Canagliflozin vs Nivolumab

Canagliflozin vs Nivolumab: Overview

This comparison examines the pharmacological differences between Canagliflozin and Nivolumab.

Mechanism of Action

Canagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Canagliflozin — 10.6 hours; Nivolumab — 27 days.

Chemical Properties

Molecular Formula: Canagliflozin — C24H25FO5S.

Molecular Weight: Canagliflozin — 444.5170 g/mol.

Type: Canagliflozin — Small molecule; Nivolumab — Antibody.